OSUR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. OSUR is trading ~2.79 pre-market (right at/above the key R1 resistance 2.788) after a weak fundamental quarter (2025/Q3 revenue -32% YoY) and with hedge funds aggressively selling. With no Intellectia buy signals today and pattern-based downside odds (80% chance of further declines over 1d/1w/1m), the risk/reward is unfavorable for an impatient entry at resistance—avoid buying here.
Trend/levels: Pre-market 2.79 is essentially sitting on the first resistance (R1=2.788) with the next overhead level near R2=2.84; nearest pivot support is 2.704 and then 2.62/2.568. Momentum: MACD histogram is slightly positive (0.0083) and expanding, implying a nascent bullish momentum attempt, but moving averages are converging (no strong established uptrend). RSI(6)=64.6 is near the upper-neutral zone—more consistent with a short-term bounce that may be getting stretched into resistance rather than a fresh low-risk entry. Net: technically improving, but the entry is poorly positioned (at resistance) and vulnerable to rejection back toward ~2.70/2.62.
Profitability trend improving: net loss and EPS both improved materially YoY in 2025/Q3 (loss narrowing).
Gross margin modestly higher YoY (43.46%).
Upcoming earnings on 2026-02-24 (after hours) can act as a catalyst if guidance stabilizes revenue.
Early technical momentum improvement (MACD turning positive).
Demand/revenue weakness: 2025/Q3 revenue fell -32.14% YoY, a major negative trend.
Hedge funds are selling aggressively (selling amount up ~2277% QoQ), a bearish positioning signal.
No Intellectia proprietary buy signals today (AI Stock Picker: none; SwingMax: none).
Pattern-based forward stats are bearish: estimated 80% chance of -2.16% next day, -4.1% next week, -13.32% next month.
Price is at/just above resistance (R1~2.788), increasing near-term pullback risk.
Latest quarter: 2025/Q3. Revenue declined to 27.085M (-32.14% YoY), showing significant top-line contraction. However, profitability metrics improved: net income rose to -13.712M (loss narrowed; +204.24% YoY), EPS improved to -0.19 (+216.67% YoY), and gross margin increased to 43.46% (+1.61% YoY). Overall: better cost/margin execution, but the growth trend is negative due to the sharp revenue drop—this weakens the case for buying immediately.
No analyst rating/price-target change data was provided, so a recent trend summary can’t be confirmed. Practical Wall Street-style pros/cons view from the available data: Pros—improving margins and narrowing losses, potential event catalyst at next earnings. Cons—material revenue contraction, small-cap risk profile, and heavy institutional/hedge-fund selling signals deteriorating confidence.
